These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25735000)

  • 1. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine.
    Cernuda-Morollón E; Ramón C; Martínez-Camblor P; Serrano-Pertierra E; Larrosa D; Pascual J
    Pain; 2015 May; 156(5):820-824. PubMed ID: 25735000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
    Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
    Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
    Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 5. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
    Cernuda-Morollón E; Larrosa D; Ramón C; Vega J; Martínez-Camblor P; Pascual J
    Neurology; 2013 Oct; 81(14):1191-6. PubMed ID: 23975872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine.
    Domínguez Vivero C; Leira Y; Saavedra Piñeiro M; Rodríguez-Osorio X; Ramos-Cabrer P; Villalba Martín C; Sobrino T; Campos F; Castillo J; Leira R
    Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32731573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
    Pérez-Pereda S; Toriello-Suárez M; Ocejo-Vinyals G; Guiral-Foz S; Castillo-Obeso J; Montes-Gómez S; Martínez-Nieto RM; Iglesias F; González-Quintanilla V; Oterino A
    Mol Biol Rep; 2020 Sep; 47(9):7125-7138. PubMed ID: 32951099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine.
    Ramón C; Cernuda-Morollón E; Pascual J
    Curr Opin Neurol; 2017 Jun; 30(3):281-286. PubMed ID: 28234796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interictal amylin levels in chronic migraine patients: A case-control study.
    Irimia P; Martínez-Valbuena I; Mínguez-Olaondo A; Domínguez-Vivero C; Sánchez-Arias JA; Martínez-Vila E; Luquin MR; Leira R
    Cephalalgia; 2021 Apr; 41(5):604-612. PubMed ID: 33269952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
    Cernuda-Morollón E; Ramón C; Larrosa D; Alvarez R; Riesco N; Pascual J
    Cephalalgia; 2015 Sep; 35(10):864-8. PubMed ID: 25431141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal.
    Lee MJ; Lee SY; Cho S; Kang ES; Chung CS
    J Headache Pain; 2018 Jul; 19(1):53. PubMed ID: 30006780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
    Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs.
    Leira Y; Domínguez C; Ameijeira P; López-Arias E; Ávila-Gómez P; Pérez-Mato M; Sobrino T; Campos F; Blanco J; Leira R
    Sci Rep; 2021 Jan; 11(1):1092. PubMed ID: 33441852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in circulating alpha-calcitonin gene-related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study.
    Pascual-Mato M; Gárate G; González-Quintanilla V; Madera-Fernández J; Castro B; García MJ; Crespo J; Rivero M; Pascual J
    Headache; 2024; 64(7):849-858. PubMed ID: 38922858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide].
    Garcia-Estevez DA; Pardo-Parrado M; Silvarrey-Rodriguez S
    Rev Neurol; 2017 Aug; 65(4):153-156. PubMed ID: 28726232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
    Salim A; Hennessy E; Sonneborn C; Hogue O; Biswas S; Mays M; Suneja A; Ahmed Z; Mata IF
    CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs "customized" dosing/injection paradigm.
    Green MW; Rothrock JF
    Toxicon; 2018 Jun; 147():116-119. PubMed ID: 29596847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
    Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
    J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
    Eren OE; Gaul C; Peikert A; Gendolla A; Ruscheweyh R; Straube A
    Sci Rep; 2020 Jul; 10(1):11382. PubMed ID: 32647152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.